Table 2

Use of replacement estrogens and risk of renal cell carcinoma

CasesaControlsaORb (95% CI)ORc (95% CI)
Ever used replacement estrogens
 No2272411.01.0
 Yes1921791.2 (0.9–1.6)1.0 (0.7–1.3)
Oral estrogens only1701541.2 (0.9–1.7)1.0 (0.7–1.4)
Usual monthly dose of estrogen pills (mg)d
 <1540331.4 (0.8–2.5)1.2 (0.6–2.1)
 15–<2537331.3 (0.9–2.2)1.1 (0.6–1.9)
 25+51431.4 (0.9–2.2)1.0 (0.6–1.6)
Cumulative lifetime dose of estrogen (mg)d
 <47333371.0 (0.6–1.7)0.8 (0.5–1.4)
 473–<198040351.5 (0.9–2.5)1.2 (0.7–2.1)
 1980+55371.8 (1.1–3.0)1.3 (0.7–2.2)
  • a Three cases and two controls were excluded from the analysis due to unknown status of estrogen replacement use.

  • b Adjusted for level of education.

  • c Adjusted for level of education and history of hysterectomy.

  • d The sum was less than the total number of users due to the exclusion of subjects with a missing dose in the analysis.